Last quarter (Q4 2024), Outlook Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Outlook Therapeutics's net income was $5.69M. See Outlook Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 24	Sep 23	Sep 22	Sep 21	Sep 20
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ 71.70M	$ 71.70M	$ 53.13M	$ 63.07M	$ 51.73M	$ 36.84M
Operating Income	$ -71.70M	$ -71.70M	$ -53.13M	$ -63.07M	$ -51.73M	$ -36.84M
Net Non Operating Interest Income Expense	$ 906.15K	$ 906.15K	$ 971.48K	$ -1.49M	$ -936.13K	$ -1.76M
Other Income Expense	$ -38.54M	$ -38.54M	$ 537.74K	$ -1.49M	$ 498.49K	$ 1.88M
Pretax Income	$ -74.37M	$ -75.36M	$ -58.98M	$ -66.05M	$ -53.16M	$ -38.51M
Tax Provision	$ 2.80K	$ 2.80K	$ 2.80K	$ 2.80K	$ 2.00K	$ -3.27M
Earnings From Equity Interest Net Of Tax	$ -100.74K	$ -100.74K	$ -11.00K	$ -48.73K	$ -46.34K	$ ―
Net Income Common Stockholders	$ -75.37M	$ -75.37M	$ -58.98M	$ -66.05M	$ -53.16M	$ -48.87M
Basic EPS	$ -4.82	$ -4.06	$ -4.80	$ -6.20	$ -7.00	$ -13.40
Diluted EPS	$ -4.82	$ -4.06	$ -4.80	$ -6.20	$ -7.00	$ -13.40
Basic Average Shares	$ 74.24M	$ 18.55M	$ 12.51M	$ 10.60M	$ 7.63M	$ 3.63M
Diluted Average Shares	$ 76.49M	$ 18.55M	$ 12.51M	$ 10.60M	$ 7.63M	$ 3.63M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 71.70M	$ 71.70M	$ 53.13M	$ 63.07M	$ 51.73M	$ 36.84M
Net Income From Continuing And Discontinued Operation	$ -75.37M	$ -75.37M	$ -58.98M	$ -66.05M	$ -53.16M	$ -35.24M
Normalized Income	$ -74.61M	$ -74.61M	$ ―	$ ―	$ -42.00M	$ ―
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -75.31M	$ -75.36M	$ -58.98M	$ -64.56M	$ -52.23M	$ -36.75M
EBITDA	$ -75.23M	$ -75.25M	$ -58.93M	$ -64.36M	$ -51.96M	$ -36.20M

Currency in USD

Outlook Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing